ArticleCancer research2026
Microglial TBK1 Signaling Promotes Breast Cancer Brain Metastasis.
Article in Cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- TFAM loss drives oxaliplatin resistance by linking mtDNA release to STING-TBK1-mediated lysophagy.Oncogene · 2026Article
- Tumor microenvironment and signaling pathways in melanoma brain metastasis.Annals of translational medicine · 2026Review
- Targeting the neuro-immune crosstalk in breast cancer brain metastases.Journal for immunotherapy of cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Breast cancer brain metastasis (BCBM) is the most common and lethal form of brain tumor, marked by abundant infiltration of tumor-associated microglia (TAMG). TAMG can promote the seeding and growth of metastatic breast cancer cells, highlighting the need to elucidate the molecular mechanisms underlying their function to enable the development of effective strategies to target TAMG in BCBM. In this study, using tumor samples from patients with BCBM and mouse models, and in vitro microglia culture systems, we demonstrated that TANK-binding kinase 1 (TBK1) signaling is enriched and activated in TAMG. TBK1 inhibition in TAMG reduced epithelial-mesenchymal transition, migration, invasion, and proliferation of breast cancer cells. Through integrated analyses of transcriptomic profiles, patient survival data, and secretome dataset, followed by experimental validation, GM-CSF was identified as the key secreted protein mediating TBK1-regulated metastatic behaviors of breast cancer cells. Pharmacologic inhibition of TBK1 in BCBM mouse models reduces BCBM and extends survival. Together, these data indicate that TBK1 signaling in TAMG contributes to BCBM and, along with its downstream effector GM-CSF, represents a promising therapeutic target for this deadly disease. SIGNIFICANCE: Enrichment and activation of TBK1 in tumor-associated microglia upregulates GM-CSF to promote metastatic properties of breast cancer cells, highlighting TBK1 inhibition as a potential therapeutic opportunity for treating breast cancer brain metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.